黄金城集团

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Use of CRISPR/Cas ribonucleoproteins for high throughput gene editing of induced pluripotent stem cells

Methods. 2021-02; 
Qi Wang, Sueanne Chear, Kristof Wing, David Stellon, Minh Thuan Nguyen Tran, Jana Talbot, Alice Pébay, Alex W Hewitt, Anthony L Cook
Products/Services Used Details Operation
Synthetic sgRNA and crRNA Service … The commercial availability of various ‘nickase’ variants of Cas9 (eg IDT 1,081,062 and 1081064; Genscript Z03390-10) similarly provides other avenues for gene editing, and which … Get A Quote

摘要

Induced pluripotent stem cells (iPSCs) have become widely used for disease modelling, particularly with regard to predisposing genetic risk factors and causal gene variants. Alongside this, technologies such as the CRISPR/Cas system have been adapted to enable programmable gene editing in human cells. When combined, CRISPR/Cas gene editing of donor-specific iPSC to generate isogenic cell lines that differ only at specific gene variants provides a powerful model with which to investigate genetic variants associated with diseases affecting many organs, including the brain and eye. Here we describe our optimized protocol for using CRISPR/Cas ribonucleoproteins to edit disease causing gene variants in human iPSCs. ... More

关键词

CRISPR/Cas ribonucleoprotein, Induced pluripotent stem cells, Isogenic